Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell D Hull

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Thrombosis and Haemostasis|October 3, 2013
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trialRoger D Yusen, Russell D Hull, Sebastian M Schellong, et al.
Thrombosis and Haemostasis|December 7, 2017
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX TrialGerald Chi, Samuel Z Goldhaber, Russell D Hull, et al.
Annals of Internal Medicine|July 13, 2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trialRussell D Hull, Sebastian M Schellong, Victor F Tapson, et al.
Annals of Internal Medicine|April 21, 2004
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic reviewPaul D Stein, Russell D Hull, Kalpesh C Patel, et al.
The Journal of Invasive Cardiology|May 5, 2010
Outcomes with retrievable inferior vena cava filtersMuhammad Janjua, Fahad Younas, Irfan Moinuddin, et al.
Circulation|December 28, 2017
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial)Gerald Chi, Megan K Yee, Alpesh N Amin, et al.
The American Journal of Medicine|January 9, 2007
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harmsRussell D Hull, Graham F Pineo, Rollin F Brant, et al.
The American Journal of Medicine|December 6, 2006
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerRussell D Hull, Graham F Pineo, Rollin F Brant, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|May 20, 2004
Uptake of new treatment strategies for deep vein thrombosis: an international auditDrahomir A Aujesky, Jacques Cornuz, Jean-Luc Bosson, et al.
The American Journal of Medicine|January 12, 2008
Enlarged right ventricle without shock in acute pulmonary embolism: prognosisPaul D Stein, Afzal Beemath, Fadi Matta, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Thrombosis and Haemostasis|October 3, 2013
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trialRoger D Yusen, Russell D Hull, Sebastian M Schellong, et al.
Thrombosis and Haemostasis|December 7, 2017
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX TrialGerald Chi, Samuel Z Goldhaber, Russell D Hull, et al.
Annals of Internal Medicine|July 13, 2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trialRussell D Hull, Sebastian M Schellong, Victor F Tapson, et al.
Annals of Internal Medicine|April 21, 2004
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic reviewPaul D Stein, Russell D Hull, Kalpesh C Patel, et al.
The Journal of Invasive Cardiology|May 5, 2010
Outcomes with retrievable inferior vena cava filtersMuhammad Janjua, Fahad Younas, Irfan Moinuddin, et al.
Circulation|December 28, 2017
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial)Gerald Chi, Megan K Yee, Alpesh N Amin, et al.
The American Journal of Medicine|January 9, 2007
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harmsRussell D Hull, Graham F Pineo, Rollin F Brant, et al.
The American Journal of Medicine|December 6, 2006
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerRussell D Hull, Graham F Pineo, Rollin F Brant, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|May 20, 2004
Uptake of new treatment strategies for deep vein thrombosis: an international auditDrahomir A Aujesky, Jacques Cornuz, Jean-Luc Bosson, et al.
The American Journal of Medicine|January 12, 2008
Enlarged right ventricle without shock in acute pulmonary embolism: prognosisPaul D Stein, Afzal Beemath, Fadi Matta, et al.
Pageof 13